Shares of Valeant Pharmaceuticals (VRX) rose some 2.5% in
Wednesday's trading session. The specialty pharmaceutical company announced the
acquisition of Obagi Medical Products (OMPI).
The Deal
Valeant Pharmaceuticals announced that is has agreed to acquire Obagi Medical Products, a leader in topical aesthetic and therapeutic skin-health systems. The company is known from leading dermatology brands including Obagi Nu-Derm, Condition & Enhance and Obagi-C, among others.
Valeant will pay $19.75 per share in cash for Obagi Medical, valuing the company around $344 million. The deal value represents a 28% premium compared to Tuesday's closing price.
Read the entire article on Seekingalpha by clicking the following link
The Deal
Valeant Pharmaceuticals announced that is has agreed to acquire Obagi Medical Products, a leader in topical aesthetic and therapeutic skin-health systems. The company is known from leading dermatology brands including Obagi Nu-Derm, Condition & Enhance and Obagi-C, among others.
Valeant will pay $19.75 per share in cash for Obagi Medical, valuing the company around $344 million. The deal value represents a 28% premium compared to Tuesday's closing price.
Read the entire article on Seekingalpha by clicking the following link
No comments:
Post a Comment